Related Experiment Video
Updated: Jun 23, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Safety and efficacy of ibutilide in heart transplant recipients
José A Tallaj1, Veronica Franco, Barry K Rayburn
1Division of Cardiovascular Disease, Section of Heart Failure, Transplantation and Pulmonary Vascular Disease, University of Alabama at Birmingham, Birmingham, AL 35294, USA. jtallaj@uab.edu
In this report we describe our experience with ibutilide, a relatively new Class III anti-arrhythmic agent, in 8 heart transplant patients with supraventricular tachycardia in various settings (3 patients with rejection, 2 after endomyocardial biopsy). Ibutilide treatment was successful in all patients, with the arrhythmia recurring early in 1 patient. There were no complications.
In this report we describe our experience with ibutilide, a relatively new Class III anti-arrhythmic agent, in 8 heart transplant patients with supraventricular tachycardia in various settings (3 patients with rejection, 2 after endomyocardial biopsy). Ibutilide treatment was successful in all patients, with the arrhythmia recurring early in 1 patient. There were no complications.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Heart Failure Drugs: Inotropic Agents
Kidney Transplant I: Introduction
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

